Latest Pharma Insights
ESMO 2026: Takeda Reaches First Summit With Claudin18.2 ADC
The lead prospect from the Japanese firm’s Innovent deal last year, arcotatug tavatecan, has got off to a good start in the Phase III G-HOPE-001 gastric cancer trial but still needs to prove itself in in western markets and in a broader patient population.
Scrip - October 24, 2026
The lead prospect from the Japanese firm’s Innovent deal last year, arcotatug tavatecan, has got off to a good start in the Phase III G-HOPE-001 gastric cancer trial but still needs to prove itself in in western markets and in a broader patient population.
Scrip - October 24, 2026
CMR Surgical Chose Agency Over Distribution To Keep Surgeons Close, CEO Says
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
ESMO 2026: Takeda Reaches First Summit With Claudin18.2 ADC
The lead prospect from the Japanese firm’s Innovent deal last year, arcotatug tavatecan, has got off to a good start in the Phase III G-HOPE-001 gastric cancer trial but still needs to prove itself in in western markets and in a broader patient population.
Scrip - October 24, 2026
The lead prospect from the Japanese firm’s Innovent deal last year, arcotatug tavatecan, has got off to a good start in the Phase III G-HOPE-001 gastric cancer trial but still needs to prove itself in in western markets and in a broader patient population.
Scrip - October 24, 2026
CMR Surgical Chose Agency Over Distribution To Keep Surgeons Close, CEO Says
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
P&G To Bolster Thorne’s Growth Without Taking Reins – CFO
P&G plans to help Thorne scale its business with supply chain, ingredient qualification and marketing capabilities while retaining the team and allowing it to lead the brand’s growth strategy.
HBW Insight - October 23, 2026
P&G plans to help Thorne scale its business with supply chain, ingredient qualification and marketing capabilities while retaining the team and allowing it to lead the brand’s growth strategy.
HBW Insight - October 23, 2026
L’Oréal CEO: GLP-1s Are Reshaping Skin Care Demand
L’Oréal CEO Nicolas Hieronimus says the company is responding to the GLP-1 weight loss trend with formulas that address the negative impact of the drugs on skin’s appearance, while also investing in formulas that address skin care needs before, during and after aesthetic treatments.
HBW Insight - October 23, 2026
L’Oréal CEO Nicolas Hieronimus says the company is responding to the GLP-1 weight loss trend with formulas that address the negative impact of the drugs on skin’s appearance, while also investing in formulas that address skin care needs before, during and after aesthetic treatments.
HBW Insight - October 23, 2026
Zydus Receives FDA Approval For First Generic Climara Pro
The US regulator has approved Zydus’s once-weekly transdermal hormone therapy patch for estradiol and levonorgestrel as a competitive generic therapy, triggering eligibility for a 180-day exclusivity period.
Generics Bulletin - October 23, 2026
The US regulator has approved Zydus’s once-weekly transdermal hormone therapy patch for estradiol and levonorgestrel as a competitive generic therapy, triggering eligibility for a 180-day exclusivity period.
Generics Bulletin - October 23, 2026
France’s Alma Urges Off-Patent Exemption From Latest Legislative Burdens
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
Formycon Goes After Its First Niche-Buster Biosimilar With A Latin American Partner
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
The Biological Case for Adopting New Approach Methodologies in Oncology
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026